|Bid||1.6800 x 900|
|Ask||1.7600 x 1000|
|Day's Range||1.6900 - 1.7500|
|52 Week Range||1.3500 - 2.6600|
|Beta (3Y Monthly)||1.68|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Celsion Corporation (CLSN), an oncology drug development company, today announced it has received approval from the New Jersey Economic Development Authority’s (NJEDA) Technology Business Tax Certificate Transfer (NOL) program to sell the Company’s unused New Jersey net operating losses (NOLs) and R&D tax credits. The exact percentage of NOL’s to be sold will be determined by the NJEDA after reviewing all qualified applications. In 2018, the Company received approval from the NJEDA to sell $11.1 million of its unused New Jersey net operating losses for the tax years 2011 through 2017 and was able to transfer this credit and receive approximately $10.5 million of net cash proceeds in the fourth quarter of 2018.
Celsion Corporation (CLSN), an oncology drug-development company, announces that Michael Tardugno, Chairman, President and Chief Executive Officer and Khursheed Anwer, Executive Vice President and Chief Scientific Officer will present at the Chardan 3rd Annual Genetic Medicines Conference on Monday, October 7, 2019 at 9:00 a.m. Eastern time. Management’s participation will take the form of a “Fireside Chat” and will primarily focus on the Company’s development program for GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer.
Celsion Corporation (CLSN), an oncology drug-development company, announces it co-sponsored a symposium focused on hepatocellular carcinoma (HCC) at the recent 13th Annual Conference of the International Liver Cancer Association (ILCA). Other sponsors included Bayer Healthcare Pharmaceuticals, Inc. and Exelixis, Inc., both of whom provide therapeutics for the treatment of advanced HCC. The symposium’s timing verges on the upcoming meeting of the Data Monitoring Committee’s review of the first interim data for the Company’s Phase III OPTIMA Study of its lead drug candidate, ThermoDox®, to treat HCC.
Celsion Corporation (CLSN), an oncology drug-development company, announces that a study from a single site in China titled “Thermosensitive liposomal doxorubicin plus radiofrequency ablation increased tumor destruction and improved survival in patients with medium and large hepatocellular carcinoma: A randomized, double-blinded, dummy-controlled clinical trial in a single center” has been published in the Journal of Cancer Research and Therapeutics. The data from this single site at the Peking University Cancer Hospital and Institute in Beijing show an overall survival (OS) improvement of 22.5 months in patients with 3-7 cm unresectable hepatocellular carcinoma (HCC) tumors receiving combined radiofrequency ablation (RFA) and ThermoDox®, compared with the use of RFA alone.
First Pre-Planned Efficacy Analysis of the Phase III OPTIMA Study Planned for Mid-October Strong Balance Sheet Plus the Non-Dilutive Sale of $4 Million of New.
NIH’s Independent Analysis of Celsion’s Phase III HEAT Study Confirms Increasing Radiofrequency Ablation (RFA) Heating Time + ThermoDox® Improves Overall Survival with.
Celsion Corporation (CLSN), an oncology drug-development company, announces that Premal H. Thaker, M.D., MSc., Professor of Obstetrics and Gynecology-Division of Gynecologic Oncology at Washington University School of Medicine in St. Louis, led an expert call on the ovarian cancer treatment landscape and emerging opportunities hosted by Oppenheimer & Co. Inc. on August 8th. Dr. Thaker is active in the development of GEN-1, Celsion’s DNA-based, IL-12 immunotherapy for the treatment of ovarian cancer.
LAWRENCEVILLE, N.J., Aug. 08, 2019 -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the.
Celsion Corporation (CLSN), an oncology drug-development company, announces the prescribed number of events has been reached for the first prespecified interim analysis of the OPTIMA Phase III Study with ThermoDox® plus RFA (radiofrequency ablation) in patients with hepatocellular carcinoma (HCC), or primary liver cancer. Following preparation of the data, the first interim analysis will be conducted by the Independent Data Monitoring Committee (iDMC). The Company expects the iDMC meeting to occur by mid-October.
Celsion Corporation (CLSN), an oncology drug-development company, announces that the University Medical Center Utrecht in the Netherlands has received Institutional Review Board (IRB) approval to begin a Phase I study to determine the safety, tolerability and feasibility of ThermoDox® (lyso-thermosensitive liposomal doxorubicin) in combination with Magnetic Resonance Guided High Intensity Focused Ultrasound (MR-HIFU) hyperthermia and cyclophosphamide therapy for the local treatment of the primary tumor in metastatic breast cancer (mBC).
NEW YORK, NY / ACCESSWIRE / May 15, 2019 / Celsion Corp. (NASDAQ: CLSN ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 15, 2019 at 11:00 AM Eastern Time. ...
Company to Hold Conference Call on Wednesday, May 15, 2019 at 11:00 a.m. EDT LAWRENCEVILLE, N.J, May 15, 2019 -- Celsion Corporation (NASDAQ: CLSN), an oncology drug.
LAWRENCEVILLE, N.J., May 08, 2019 -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the.
Celsion Corporation (CLSN), a clinical stage oncology drug development company, today announced that the United States Patent and Trademark Office has granted U.S. Patent No. 10,251,901 B2 – Thermosensitive Nanoparticle Formulations and Method of Making the Same, which is directly applicable to the method of treating cancer using a new ThermoDox® formulation. This new patent strengthens the coverage of ThermoDox®, Celsion’s heat-activated liposomal platform technology, currently in Phase III development for the treatment of primary liver cancer, also known as hepatocellular carcinoma (HCC). The Company’s pivotal 556-patient global Phase III OPTIMA Study in HCC completed enrollment in August 2018 at 65 clinical sites in North America, Europe, China, S. Korea, Taiwan, and Southeast Asia.
Company to Discuss its Ongoing Pivotal Phase III Study in Primary Liver Cancer and its Phase I/II Clinical Study in Ovarian Cancer LAWRENCEVILLE, N.J., April 12, 2019 --.
LAWRENCEVILLE, N.J., April 12, 2019 -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the.
NEW YORK , April 11, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...
Celsion Enters 2019 with a Strong Balance Sheet, Clean Capitalization Structure and an Advancing Clinical Pipeline Company to Hold Conference Call on Friday, March 29, 2019.
LAWRENCEVILLE, N.J, March 22, 2019 -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the year.
100% Objective Response Rates and 88% Complete (R0) Resection Rates in Highest Dose Cohorts GEN-1 Intraperitoneally Delivered Durable Local Levels of Pro-Immune IL-12 and.
Celsion Corporation (CLSN), an oncology drug development company, today announced that on February 19, 2019, the Compensation Committee of the Company's Board of Directors approved the grant of (i) inducement stock options (the “Inducement Option Grants”) to purchase a total of 140,004 shares of common stock and (ii) restricted stock grants (the “Inducement Stock Grants”) totaling 13,000 shares of common stock to two new employees. Each of the Inducement Option Grants has an exercise price per share equal to $2.18, the closing price of Celsion’s common stock as reported by Nasdaq on February 19, 2019.
NEW YORK, Feb. 01, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
LAWRENCEVILLE, N.J., Jan. 24, 2019 -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that Jeffrey Church, Celsion’s Executive Vice.
Celsion Corporation (CLSN), an oncology drug development company, today announced that results from the Phase I TARDOX trial of ThermoDox® conducted at the University of Oxford, United Kingdom, were published in the peer-reviewed journal, Radiology. The TARDOX trial evaluated the safety and efficacy of ThermoDox®, Celsion’s proprietary heat-activated liposomal encapsulation of doxorubicin, along with focused ultrasound for the treatment of liver cancer. The article, titled, “Focused Ultrasound Hyperthermia for Targeted Drug Release from Thermosensitive Liposomes: Results from a Phase I Trial,” included an evaluation of the TARDOX results and the safety, efficacy and utility of treatment with ThermoDox® plus targeted, non-invasive hyperthermic ultrasound in patients with solid liver tumors, with treatment plans based on patient-specific modeling.
Celsion Corporation (CLSN), an oncology drug development company, today announced that data from a Phase I study of GEN-1, its DNA-based immunotherapy for the localized treatment of ovarian cancer as an adjuvant to chemotherapy current standard of care, has been selected for oral presentation at the upcoming ASCO-SITC Clinical Immuno-Oncology Symposium held in San Francisco on Feb. 28 through March 2, 2019. The abstract titled, “Phase I study of the safety and activity of formulated IL-12 plasmid administered intraperitoneally in combination with neoadjuvant chemotherapy in patients with newly diagnosed advanced stage ovarian cancer,” was featured as a “Highlights” Abstract by ASCO-SITC and will be presented by Premal H. Thaker, M.D., M.S., Professor of Obstetrics and Gynecology at the Siteman Cancer Center at the Washington University School of Medicine in St. Louis, Mo. and investigator in Celsion’s GEN-1 development program.